Hoth Therapeutics (HOTH) announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide, or ASO, ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

As demand soared for weight-loss drugs, price signals worked.

SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics ...

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching artificial intelligence and emerging ...

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely be key in determining the impact of GLP-1s on plan costs. Celebrity ...

Semaglutide, the GLP-1 agonist drug that powers Wegovy, could cost less than $100,000 per qualify-adjusted life year added once its price falls to $1,522 per year, from an average of about $8,412 ...

The number of people without diabetes taking a GLP-1 drug more than tripled between 2018 and 2022 in the United States, researchers reported Monday in the Annals of Internal Medicine. Spending on ...

Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. Introducing Hot Shots, a series that examines how Ozempic and other GLP-1 drugs ...